Chimeric antigen receptors targeting B-cell maturation antigen

The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further...

Full description

Saved in:
Bibliographic Details
Main Authors GALETTO, Roman, PERTEL, Thomas Charles, JUILLERAT, Alexandre, BOLDAJIPOUR, Bijan Andre, VALTON, Julien, SOMMER, Cesar Adolfo, KUO, Tracy Chia-Chien, SASU, Barbra Johnson, VAN BLARCOM, Thomas John, RAJPAL, Arvind, CHAPARRO RIGGERS, Javier Fernando, DUCHATEAU, Philippe
Format Patent
LanguageEnglish
Published 14.09.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
Bibliography:Application Number: AU20230219928